Among patients with OAB, anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
There is no evidence for an association between cerebral β-amyloid deposition, a marker of Alzheimer disease, and intracranial atherosclerotic plaque or stenosis.
Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
Compared with their peers, Asian patients with dementia were less likely to be prescribed antidementia drugs, and they received these drugs for fewer days per year.
